06:56 AM EDT, 10/23/2024 (MT Newswires) -- (Updates with Eli Lilly's ( LLY ) response in the fourth paragraph.)

Mangoceuticals ( MGRX ) said late Monday it "strongly refutes" Eli Lilly's ( LLY ) claims that the company "improperly" imitated its weight-loss Zepbound and Mounjaro medicines.

"MangoRx strongly refutes any and all claims made by Eli Lilly ( LLY ) regarding the sale of compounded tirzepatide," the company added.

Eli Lilly ( LLY ) filed lawsuits against medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its weight-loss drug Zepbound.

"Lilly filed three lawsuits yesterday [Monday] against entities engaging in conduct that poses serious risks to patient safety," an Eli Lilly ( LLY ) spokesperson told MT Newswires in an email late Tuesday. "Two unlawfully tout the efficacy of their manipulated tirzepatide knockoffs-an oral tirzepatide pill and tirzepatide mixed with vitamin B12-even though neither has been clinically tested, let alone reviewed by FDA for safety or efficacy. The other offers "research purposes only" tirzepatide for weight loss, which is not fit for human use. No one should ever be allowed to sell these untested, non-human grade or manipulated drugs to American consumers."

Price: 2.4000, Change: -0.11, Percent Change: -4.38